Patient-reported outcomes and tolerability in patients receiving ripretinib versus sunitinib after treatment with imatinib in INTRIGUE, a phase 3, open-label study1

Simple item page
dc.contributor.authorGelderblom, Hans
dc.contributor.authorJones, Robin L.
dc.contributor.authorBlay, Jean-Yves
dc.contributor.authorGeorge, Suzanne
dc.contributor.authorvon Mehren, Margaret
dc.contributor.authorZalcberg, John R.
dc.contributor.authorKang, Yoon-Koo
dc.contributor.authorRazak, Albiruni Abdul
dc.contributor.authorTrent, Jonathan
dc.contributor.authorAttia, Steven
dc.contributor.authorLe Cesne, Axel
dc.contributor.authorSiontis, Brittany L.
dc.contributor.authorGoldstein, David
dc.contributor.authorBoye, Kjetil
dc.contributor.authorSanchez, Cesar
dc.contributor.authorSteeghs, Neeltje
dc.contributor.authorRutkowski, Piotr
dc.contributor.authorDruta, Mihaela
dc.contributor.authorSerrano, Cesar
dc.contributor.authorSomaiah, Neeta
dc.contributor.authorChi, Ping
dc.contributor.authorHarrow, Brooke
dc.contributor.authorBecker, Claus
dc.contributor.authorReichmann, William
dc.contributor.authorSherman, Matthew L.
dc.contributor.authorRuiz-Soto, Rodrigo
dc.contributor.authorHeinrich, Michael C.
dc.date.accessioned2025-01-20T20:06:03Z
dc.date.available2025-01-20T20:06:03Z
dc.date.issued2023
dc.description.abstractPurpose: In the INTRIGUE trial, ripretinib showed no significant difference versus sunitinib in progression-free survival for patients with advanced gastrointestinal stromal tumour (GIST) previously treated with imatinib. We compared the impact of these treatments on health-related quality of life (HRQoL).Patients and methods: Patients were randomised 1:1 to once-daily ripretinib 150 mg or once daily sunitinib 50 mg (4 weeks on/2 weeks off). Patient-reported outcomes were assessed using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire for Cancer-30 (EORTC QLQ-C30) questionnaire at day (D)1, and D29 of all cycles until treatment discontinuation. Change from baseline was calculated. Time without symptoms or toxicity (TWiST) was estimated as the mean number of days without progression, death, or grade & GE;3 treatment-emergent adverse events per patient over 1 year of follow-up.Results: Questionnaire completion at baseline was 88.1% (199/226) for ripretinib and 87.7% (199/227) for sunitinib and remained high for enrolled patients throughout treatment. Patients receiving sunitinib demonstrated within-cycle variation in self-reported HRQoL, corresponding to the on/off dosing regimen. Patients receiving ripretinib reported better HRQoL at D29 assessments than patients receiving sunitinib on all scales except constipation. HRQoL was similar between treatments at D1 assessments, following 2 weeks without treatment for sunitinib patients. TWiST was greater for ripretinib patients (173 versus 126 days).Conclusion: Patients receiving ripretinib experienced better HRQoL than patients receiving sunitinib during the dosing period and similar HRQoL to patients who had not received sunitinib for 2 weeks for all QLQ-C30 domains except constipation. Ripretinib may provide clinically meaningful benefit to patients with advanced GIST previously treated with imatinib.& COPY; 2023 Deciphera Pharmaceuticals LLC. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
dc.fuente.origenWOS
dc.identifier.doi10.1016/j.ejca.2023.113245
dc.identifier.eissn1879-0852
dc.identifier.issn0959-8049
dc.identifier.urihttps://doi.org/10.1016/j.ejca.2023.113245
dc.identifier.urihttps://repositorio.uc.cl/handle/11534/91727
dc.identifier.wosidWOS:001061894200001
dc.language.isoen
dc.revistaEuropean journal of cancer
dc.rightsacceso restringido
dc.subjectGastrointestinal stromal tumours
dc.subjectPatient reported outcome measures
dc.subjectQuality of life
dc.subjectProtein kinase inhibitors
dc.subject.ods03 Good Health and Well-being
dc.subject.odspa03 Salud y bienestar
dc.titlePatient-reported outcomes and tolerability in patients receiving ripretinib versus sunitinib after treatment with imatinib in INTRIGUE, a phase 3, open-label study1
dc.typeartículo
dc.volumen192
sipa.indexWOS
sipa.trazabilidadWOS;2025-01-12
Files
Collections
Artículos de revistas